DECIPHERA PHARMACEUTICALS IN (DCPH)
US24344T1016 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Unusual volume stocks are being observed in Wednesday's session.
The trading volume of these stocks is deviating from the norm in today's session.
In today's session, these stocks are experiencing unusual volume.
Discover the stocks with unexpected trading volume in today's session on the US markets.
ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals
/PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and...
Notable Monday Option Activity: DKS, DCPH, AAPL
Which stocks are experiencing notable movement on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates DCPH, HTLF, UMBF, HCP
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Monday Sector Leaders: Television & Radio, Drugs
Why Is Mullen Automotive (MULN) Stock Up 27% Today?
Mullen Automotive stock is climbing higher on Monday with heavy trading of MULN shares alongside it joining a new voucher program.
Citi Just Raised Its Price Target on Shopify (SHOP) Stock
Shopify stock is on the rise Monday as shares of SHOP got an increased price target and an upgrade from Citi's analysts this morning.
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Deciphera Pharmaceuticals stock is up on Monday after DCPH investors learned of a $2.4 billion acquisition deal with ONO Pharmaceutical.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
These stocks are gapping in today's session
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.
/PRNewswire/ -- Ademi LLP is investigating Deciphera (NASDAQ: DCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
The company is working on cancer treatments that block problematic kinases by targeting their switch-control pocket.
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
DCPH Makes Notable Cross Below Critical Moving Average
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) on behalf of the company's...
Commit To Purchase Deciphera Pharmaceuticals At $7.50, Earn 15.7% Annualized Using Options
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Deciphera Pharmaceuticals GAAP EPS of -$0.54 beats by $0.04, revenue of $48.3M beats by $1.72M (NASDAQ:DCPH)
Deciphera Pharmaceuticals surpasses expectations, beating Q4 earnings by $0.04 with a revenue of $48.3M, an increase of 32.9% YoY.
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Deciphera forges exclusive distribution deal with Genesis Pharma (NASDAQ:DCPH)
Deciphera Pharmaceuticals signs exclusive distribution agreement with Genesis Pharma to commercialize Ripretinib in 14 European markets for gastrointestinal...
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
